No retraction, correction or concern found when last checked on Oct 24, 2026.

PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies

Barbara W van Paassen, Anneke J van der Kooi, Karin Y van Spaendonck-Zwarts and 3 more

Orphanet Journal of Rare Diseases · 2014 · Review

Abstract

PMP22 related neuropathies comprise (1) PMP22 duplications leading to Charcot-Marie-Tooth disease type 1A (CMT1A), (2) PMP22 deletions, leading to Hereditary Neuropathy with liability to Pressure Palsies (HNPP), and (3) PMP22 point mutations, causing both phenotypes. Overall prevalence of CMT is usually reported as 1:2,500, epidemiological studies show that 20-64% of CMT patients carry the PMP22 duplication. The prevalence of HNPP is not well known. CMT1A usually presents in the first two decades with difficulty walking or running. Distal symmetrical muscle weakness and wasting and sensory loss is present, legs more frequently and more severely affected than arms. HNPP typically leads to episodic, painless, recurrent, focal motor and sensory peripheral neuropathy, preceded by minor compression on the affected nerve. Electrophysiological evaluation is needed to determine whether the polyneuropathy is demyelinating. Sonography of the nerves can be useful. Diagnosis is confirmed by finding respectively a PMP22 duplication, deletion or point mutation. Differential diagnosis includes other inherited neuropathies, and acquired polyneuropathies. The mode of inheritance is autosomal dominant and de novo mutations occur. Offspring of patients have a chance of 50% to inherit the mutation from their affected parent. Prenatal testing is possible; requests for prenatal testing are not common. Treatment is currently symptomatic and may include management by a rehabilitation physician, physiotherapist, occupational therapist and orthopaedic surgeon. Adult CMT1A patients show slow clinical progression of disease, which seems to reflect a process of normal ageing. Life expectancy is normal.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1PMP22 related neuropathies can be divided in three groups. The first group is caused by a PMP22 duplication, and constitutes the majority of Charcot-Marie-Tooth disease type 1A (CMT1A). The second group is caused by a PMP22 deletion, leading to Hereditary Neuropathy with liability to Pressure Palsies (HNPP). The third group is composed of neuropathies related to point mutations in the PMP22 gene and is classified as CMT1A or CMT1E.

Disease name

2Charcot-Marie-Tooth disease type 1A (CMT1A). Synonyms: Hereditary Motor and Sensory Neuropathy type Ia (HMSN Ia). Orphanumber ORPHA101081.

Definition

3Charcot-Marie-Tooth disease (CMT), also known as Hereditary Motor and Sensory Neuropathy (HMSN), encompasses a clinically and genetically heterogeneous group of disorders characterized by predominantly distal muscle weakness and atrophy, and sensory loss. The disease was first described in 1886 by Charcot and Marie in France and independently by Tooth in Great Britain and was named after them. CMT is the commonest inherited neuromuscular disorder. More than 45 causative genes have been identified. Despite the genetic heterogeneity, the clinical phenotype is relatively homogeneous. Classification is based on a combination of neurophysiologic characteristics, inheritance pattern, and underlying genetic cause. Based on neurophysiologic findings three different subtypes are distinguished, i.e. the demyelinating type (CMT1) defined by a motor conduction velocity (MCV) of the median or ulnar nerve of less than 38 m/s, the axonal type (CMT2) with MCV above 38 m/s, and an intermediate type. The existence of the latter is a controversial topic. Several definitions exist for the term “intermediate”. It has been used in individuals with a MCV between 30 and 40 m/s, in individuals with clinical and histopathological evidence of both abnormal myelin and axon abnormalities and in families in which members have either a demyelinating phenotype or an axonal phenotype, like families with X-linked CMT due to GJB1-mutations, with male members showing a demyelinating type and female an axonal type. CMT can be inherited in an autosomal dominant, autosomal recessive and X-linked manner. Previously, histopathological features were also applied to distinguish demyelinating from axonal neuropathy. However, nowadays, a nerve biopsy for diagnosis is considered to be obsolete. Further subclassification is based on the underlying genetic cause. CMT1A is the most common subtype of CMT1. This autosomal dominantly inherited demyelinating form of CMT is caused by a 1.5 Mb duplication on chromosome 17p11.2, containing the gene coding for peripheral myelin protein 22 (PMP22) and thus leading to three copies of the PMP22 gene.

Epidemiology

4Overall prevalence of CMT is usually reported as 1:2,500. Several more recent epidemiological studies reported prevalences of CMT ranging from 1:1,214 (in Norway) to 1:6,500 (in the United Kingdom). Epidemiological studies show that 19.6% to 64.7% of CMT patients carry the PMP22 duplication, which gives calculated prevalences of CMT1A in the range of 1:3,800 to 1:12,500.

Clinical description

5The age of onset of CMT1A is mainly in the first two decades and most frequently in the first 10 years of life. Exceptions occur as onset at birth as a floppy infant or with congenital foot deformities. Late onset at 76 years is mentioned and a case report describing siblings diagnosed at age 69 and 65 years. CMT1A usually presents as the “classical CMT” phenotype. The typical presenting symptom is difficulty walking or running, due to weakness of the distal leg muscles. CMT patients usually have distal symmetrical muscle weakness and wasting, legs (“stork appearance”) more frequently and more severely affected than arms. Calf hypertrophy instead of atrophy may also be found. Proximal weakness can be observed in up to 28% in knee extensors. Foot deformity, usually pes cavus with hammertoes, is a cardinal feature in CMT1A patients, with up to 90% of patients presenting with pes cavus. In about one third of patients this can be the presenting symptom. Clawing of the hands may occur, but is usually milder. Skeletal deformity of the spine (scoliosis) is reported in 4-35% of patients. Upper extremity symptoms include muscle weakness, primarily of intrinsic muscles, and atrophy. Decreased manual dexterity was found to be a common finding among subjects with CMT1A. Sensory symptoms are usually less prominent and can be subtle. Impaired sensation is usually found in a stocking-glove distribution with the legs more frequently and more severely affected than the arms. Large fibre sensory involvement leads to proprioceptive loss, causing balance difficulties. Small fibre sensory loss can be present with complaints of cold feet and decreased temperature discrimination sense. Pain in CMT patients is more common than previously recognized, with 55-70% of CMT1A patients reporting pain, which is considered predominantly nociceptive. Severe fatigue is reported in 60% of adult patients and is also reported in children (24%, in contrast to 14% of general school-based population). Tremor, especially of the hands, can be a feature. In some cases the tremor can be quite severe. Several CMT1A patients with tremor are described as having a Roussy-Lévy phenotype. However, the original Roussy-Lévy family carried a mutation in the MPZ gene. Nonprogressive sensorineural hearing impairment is described in CMT1A patients. Sixty-one percent of the paediatric CMT1 patients (16/18 with PMP22 duplication) showed significantly impaired speech perception ability, although they showed normal or near-normal sound detection. Vestibular impairment seems to be frequent in patients with CMT. Phrenic nerve involvement, causing dyspnoea when lying flat or nocturnal hypoventilation, is infrequent in CMT1A, but has been reported in some, severely affected, patients (in 5% and 3.5%, respectively). CMT may predispose to obstructive sleep apnoea. Only rarely patients have normal reflexes, mostly they are absent (in up to 46-75% of patients) or depressed. Hypertrophy of nerves is a feature of CMT1A, rarely clinically present and mostly established by pathology or imaging studies.

6There is large clinical variability between patients, even within the same family. Overall, 1-7% of patients become wheelchair dependent. A walking aid (cane, crutches or walker) is needed by 3-14% of patients. Dejerine-Sottas syndrome (in the past also known as Hereditary Motor and Sensory Neuropathy type III) is a hereditary neuropathy with early onset and severe presentation. Currently it is not considered a different entity, but part of the phenotypic spectrum of CMT1, because the underlying genetic defects are known CMT1 genes, like the PMP22 duplication. There are case reports on severely affected CMT patients demonstrating the presence of two mutations in two different CMT-related genes (“double trouble”). On the other side of the spectrum, patients can be asymptomatic (1.6% to 17%) or only exhibit mild symptoms, like foot deformity, leading to no or only mild problems with walking. However the term asymptomatic is questionable, as asymptomatic individuals might not experience complaints but clinical examination may show pes cavus and/or ankle jerk areflexia.

7Although always considered a disease affecting the peripheral nervous system, a recent report on 15 CMT1A patients described central nervous system involvement. Decreased white matter volume was found in 73%, with minimal, predominantly executive, cognitive disorders in 77%.

8Electrophysiologically, CMT1A is characterized by a homogeneous and diffuse motor and sensory nerve conduction slowing. Due to a combined effect of dysmyelination and axonal dysfunction and loss, sensory nerve action potentials (SNAP) are also frequently reduced in the arms and reduced to absent in the legs.

9Nerve biopsies show decreased density of myelinated nerve fibres, most pronounced in biopsies taken in the first year of life. The mean g-ratio (axon diameter versus fibre diameter) is significantly lower than normal. Characteristic onion bulb formation occurs after the age of six. Axonal loss is also found in childhood. Abnormal myelination probably extends over the whole nerve length. The most severe pathological changes were seen distally in nerves, but there were also changes in the proximal nerves and in the roots.

10An overview of the key features of CMT1A is presented in Table 1.

Aetiology

11CMT1A is predominantly caused by a 1.5 Mb duplication on chromosome 17p11.2 that includes the PMP22 gene. Cases of CMT1A with different sized duplications, most including the PMP22 gene or a copy number variant upstream of PMP22 are reported. Occasionally (<5%) point mutations in the gene are found (see “PMP22 point mutations”). Mutations in the PMP22 gene had previously been identified as the Trembler mouse mutation. Identification of an identical mutation in a CMT family showed that the PMP22 gene is also responsible for CMT1A.

12Gene dosage of PMP22 is the proposed mechanism, supported by the finding that increased PMP22 protein and elevated PMP22 messenger RNA (mRNA) was found in CMT1A patients in sural nerve biopsies. The PMP22 gene encodes a 22-kD protein that comprises 2 to 5% of peripheral nervous system myelin. PMP22 is produced primarily by Schwann cells. It is expressed in the compact portion of essentially all myelinated fibres in the peripheral nervous system. The exact function of PMP22 is still not elucidated. Studies in injured nerve suggested a role during Schwann cell growth and differentiation.

13CMT1A has been considered a primary demyelinating neuropathy, as also shown by low conduction velocities on electrophysiology in CMT1A patients. However, it has become clear that axonal dysfunction determines clinical disease severity. Onion bulbs seen on morphological studies of nerve biopsies are a sign of de- and remyelination. Evidence is accumulating that CMT1A might be a disorder of dysmyelination instead of demyelination, meaning myelination is delayed and normal myelination is never reached.

Diagnosis (diagnostic criteria and algorithms) and diagnostic methods

14If a patient presents with a chronic motor and sensory polyneuropathy, CMT should be one of the differential diagnoses. In the assessment of any patient with a polyneuropathy, the first issue to consider is whether the polyneuropathy is hereditary, by taking a detailed family history about polyneuropathies, walking difficulties or pes cavus. The mode of inheritance is autosomal dominant, but one should be aware of asymptomatic or non-diagnosed family members and a de novo rate of 10%.

15Electrophysiologic evaluation is needed to determine whether the polyneuropathy is demyelinating, axonal or intermediate. Sonography of median nerves can be helpful. It was shown that median nerve cross-sectional area (CSA) was significantly increased in CMT1A compared to CMT2, and CSA correlated with nerve conduction slowing in CMT1A.

16In autosomal dominantly inherited uniformly demyelinating sensorimotor polyneuropathy, the PMP22 duplication, the most common cause of CMT1, is tested first. In severe cases “double trouble” (the presence of two mutations in two different CMT-related genes) can be present. Currently, with the knowledge and easy accessibility of DNA diagnostics, nerve biopsy is obsolete.

Differential diagnosis

17Also in a patient without a positive autosomal dominant family history presenting with a uniformly demyelinating sensorimotor polyneuropathy, CMT1A should be considered and tested first. If DNA-testing for the PMP22 duplication is negative, other forms of CMT1 should be considered. An algorithm for genetic testing of patients with demyelinating polyneuropathy is presented in Figure 1. In view of the large number of genes involved in CMT, a gene by gene analysis is time consuming. With the introduction of Next Generation Sequencing (NGS) in clinical diagnostics the development of NGS panels for CMT is expected. The first diagnostic step in patients with demyelinating polyneuropathy should remain testing for PMP22 duplication. If negative, all the genes should be sequenced in one run (panel). Whole exome sequencing (WES) is not recommended as a first screen since the costs are still high and the sensitivity of this technology is not yet high enough. WES should only be applied to those familial cases where screening of the affected family members has proven negative. The results of the NGS panel should be discussed with geneticists with expertise in the CMT-area. Key issue in the analysis is the likelihood of the sequence variant to be pathogenic and to correspond with the patient’s phenotype and inheritance pattern. This incorporates cosegregation analysis in affected family members. If technical resources or expertise for NGS is not available, a candidate gene approach is also presented in Figure 1.

18Demyelinating polyneuropathy can also be a sign of autosomal recessive metachromatic leucodystrophy, Refsum’s disease, Krabbe’s disease, X-linked adrenomyeloneuropathy, Pelizaeus-Merzbacher syndrome and Lowe syndrome, but in addition other characteristic symptoms and signs will be present. Acquired causes associated with segmental demyelinating neuropathy, e.g. diabetes mellitus, and chronic inflammatory demyelinating polyneuropathy (CIDP) should also be considered. Typically, CIDP shows a subacute or fluctuating course, multi-focal demyelinating features on electrophysiology, high protein levels in cerebrospinal fluid, no pes cavus and a negative family history. However, in clinical practice, symptoms of CIDP and CMT can overlap. Establishing the diagnosis is important, since CIDP is treatable. Diabetes mellitus is the most common cause of neuropathy and should always be considered in a polyneuropathy patient. A distal symmetrical sensory polyneuropathy is the most common pattern of diabetic neuropathy. Diabetic neuropathy is usually axonal, but can also show demyelinating features on electrophysiology. As opposed to CMT, diabetic neuropathy has predominantly sensory and autonomic manifestations.

Genetic counselling and antenatal diagnosis

19CMT1A is inherited in an autosomal dominant fashion. Thus offspring of CMT1A patients have a chance of 50% to inherit the PMP22 duplication from their affected parent. Anticipation is described in several case studies. However, in our opinion this rather reflects phenotypic variability within a family, which is a well known phenomenon in CMT1A. The variability is likely, at least in part, due to genetic modifiers (see section “unresolved questions”).

20When the diagnosis of an inherited condition is made in a family, issues like family planning and testing of relatives at risk can arise. The best way of handling these issues, is nondirective counselling. This is based on the autonomy of the patient to make the decision that serves his/her best interests, after receiving nondirective information about benefits and disadvantages of testing, considering for instance family planning, work related choices and insurance issues. If clinically unaffected family members request predictive testing and are found to carry the PMP22 duplication, it is likely that they will develop some features, since the penetrance of the disease is nearly 100%. There is consensus about not testing minors at risk of an inherited disorder without treatment or preventive options, because of the chance of psychological harm to the child. Prenatal testing on foetal DNA is possible. During pregnancy foetal DNA can be obtained by chorionic villus sampling or by amniocentesis, both with a risk of miscarriage due to the sampling. Requests for prenatal testing for conditions that do not affect life span or intellect are not common. Requests for prenatal testing should be managed in a multidisciplinary team, involving genetic counsellors, psychologists and (paediatric) neurologists. Pre-implantation Genetic Diagnosis (PGD) is a technique used to identify genetic defects in embryos created through in vitro fertilization before pregnancy. PGD is sparsely undertaken for CMT1A. In some countries it is not considered an indication for PGD.

Management including treatment

21Treatment consists of supportive care and may include management by a rehabilitation physician, physiotherapist, occupational therapist and orthopaedic surgeon.

22Supportive care for the legs includes exercise training, shoe inlays, orthopaedic shoes and orthoses. In case of severe skeletal deformities surgical correction may be considered. However, evidence is limited; a Cochrane review concluded that methodologically sound trials are required for any of these physical interventions. Orthopaedic surgery to correct severe pes cavus or hammertoes may be helpful. Likewise, robust evidence is not present. Symptomatic treatment for the arms has not been studied extensively. Wearing a thumb opposition splint may improve manual dexterity in CMT. Tendon transfer surgery is moving a tendon from its original attachment to a new one to restore the action of the transferred muscle and improve function. It may improve thumb opposition of patients with CMT. Symptomatic drug treatment for positive sensory symptoms and for muscle cramps may be useful, but has not been investigated specifically for CMT.

23Co-existence of diabetes mellitus in a CMT1A patient is described to exacerbate symptoms of the peripheral neuropathy, and therefore optimal control of blood sugar should be strived for in a CMT patient with diabetes. Toxin or medication-induced worsening of pre-existing peripheral neuropathy is a generally known phenomenon. The use of neurotoxic agents, especially vincristine, can have a devastating effect, even in low dose and should be avoided in patients with CMT.

24Perspectives on future therapeutic developments are discussed in the “unresolved questions” section.

Prognosis

25As mentioned, axonal dysfunction determines clinical disease severity. Nerve conduction velocities are found to remain stable in children after the age of six years. There are only a few natural history studies done in adult CMT1A patients, all showing slow clinical progression. Only one 5-year natural history study included age-matched controls and showed that baseline strength and compound muscle action potential (CMAP) amplitudes were lower in patients than in controls, while adult CMT1A patients and controls had a similar decline of strength and of CMAP amplitudes over time, suggesting that progression in patients may reflect a process of normal ageing. Physical disability however increased over time in the patient group and not in the control group. This may be explained by fewer reserves in patients, as baseline strength and CMAP amplitudes were lower. Also skeletal deformations may progress. Studies about the natural history in children are ongoing. Life expectancy is normal.

Unresolved questions

26Why an increase or decrease in PMP22 gene copy number results in CMT1A or HNPP is still unknown. PMP22, also known as growth arrested specific gene 3 (GAS3), is a transmembrane protein and its expression increases upon growth arrest and in proliferating cells the levels are very low. The highest expression of PMP22 is detected in the Schwann cells of compact myelin. It is possible, that in these cells PMP22 serves another function. There is no unifying hypothesis how a PMP22 copy number variation or mutation leads to disease. In case of point mutations a toxic effect of misfolded protein is suggested, but this does not hold for the duplication and deletion of a normal copy of PMP22. In that case one can speculate that PMP22 interacts with other myelin components and stoichiometry is essential for proper function. However, there is no experimental data for this hypothesis.

27The variability of the CMT1A phenotype, even within families, suggests the presence of modifiers - genetic and/or external factors - but these have not been identified thus far. We expect that part of the variation of the phenotype is due to genetic factors. Severely affected “double trouble” cases (the presence of two mutations in two different CMT-related genes) are reported and show that known CMT genes can act as modifiers. Systematic screening of CMT genes in large cohorts of patients is necessary to identify the more common variants that affect the phenotype. With targeted NGS or whole exome sequencing probably becoming the standard in DNA diagnostics in the near future, it is expected that variants in CMT related genes will be identified, which, together with a pathogenic mutation, determine the phenotypic expression of CMT in an individual patient. Thus far, the number of reports on these double trouble cases is low. We recommend that DNA screening of other CMT genes is performed in severely affected patients carrying a PMP22 duplication.

28Variation in pathways involved in the immune system and its effect on nerve degeneration or regeneration may also affect the severity of the CMT phenotype. Analysis of transgenic models for CMT have excluded a role for B- and T-cells in the PMP22 overexpressing mice. However, alterations in the innate immune system can affect the severity of the neuropathy. Heterozygous deletion of monocyte chemoattractant protein-1 (MCP-1) does affect axonal properties and it was shown that inhibition of the complement system has a major effect on nerve degeneration and regeneration.

29Therapy for CMT1A thus far consists of supportive care only. Since the CMT1A phenotype is shown to result from a gene dosage effect, it is hypothesized that regulating the PMP22 gene dosage may be a therapeutic target. Two compounds that have been found to regulate PMP22 mRNA levels in rodent models are progesterone and ascorbic acid. Ascorbic acid did not show a beneficial effect in several randomised controlled trials. Onapristone, a progesterone receptor antagonist, reduced PMP22 mRNA levels and improved the phenotype in rodents. However, clinical trials were not initiated due to the known serious side effects in humans. No reports about progesterone antagonist treatment in CMT have been published since.

30A pilot study undertaken by Sahenk et al. showed that neurotrophin-3 (NT-3) improved the phenotype of the Trembler-J mouse and also led to slight improvement of sensory and reflex scores in CMT1A patients. Sahenk and colleagues proposed NT-3 treatment via adeno-associated virus (AAV) delivery to muscle and they showed in the Trembler-J mouse model that rAAV1.NT-3 therapy resulted in measurable NT-3 secretion levels in blood and improvement in motor function, histopathology, and electrophysiology of the peripheral nerves.

31Cell line assays for high-throughput screens are a valuable new tool to select candidates from large numbers of existing compounds. Regulatory elements in the PMP22 gene are found that direct expression of PMP22. An intronic regulatory element was coupled to the luciferase gene, creating a high-throughput screen platform. A multitude of compounds were tested on this assay, resulting in the identification of four compounds that decreased PMP22 mRNA and protein. Follow-up assays followed by animal trials are the next step.

32Two transgenic rodent models, the C3-PMP mice and the CMT-rat closely resemble human CMT1A and may be appropriate models for therapeutic studies.

33An important issue in developing treatment with drugs that showed benefit in animal studies is when to proceed to trials in patients. It can be argued that positive results in animal studies should be replicated first, before clinical trials in patients are developed.

34Effective drug treatment may be directed at normalization of the myelination process, although improvement of the axonal function should be the ultimate goal. In view of this, therapies modulating the innate immune response should not be neglected. Since axonal degeneration already starts in childhood, drug treatment beginning early in life is expected to be most beneficial.

Disease name

35Hereditary Neuropathy with liability to Pressure Palsies (HNPP). Synonymes: tomaculous neuropathy. Polyneuropathy, familial recurrent. Orphanumber ORPHA640.

Definition

36A deletion of the 1.5 Mb region on chromosome 17p11.2, the same region that is duplicated in CMT1A causes the autosomal dominantly inherited disorder Hereditary Neuropathy with liability to Pressure Palsies (HNPP). HNPP is an episodic, multifocal neuropathy. The typical clinical presentation is that of recurrent transient pressure palsies without pain, but with focal motor and sensory symptoms in the territory of a single nerve or the brachial plexus.

Epidemiology

37The prevalence of HNPP is not well known. Prevalences of 7.3 per 100,000 to 16 per 100,000 are reported.

Clinical description

38HNPP typically leads to episodic, painless, recurrent, focal motor and sensory peripheral neuropathy. It may cause attacks of numbness, muscular weakness, and atrophy. Many episodes are preceded by minor compression on the affected nerve, for instance prolonged positioning of the limb. The most vulnerable nerves are the peroneal and ulnar nerves (30-48% and 21-28%, respectively), followed by the brachial plexus (12-27%), radial nerve (4-13%) and median nerve (4-11%).

39Age at onset of first HNPP symptoms is mostly in the second or third decade, with a large range from birth (although only two cases are described, one with an transient Erb’s paresis and one with neuropathy of the peroneal nerve and pes cavus) to the eighth decade. Most patients (60-70%) present with a single, focal, acute neuropathy. Cranial nerves are affected rarely. Transient palsies of the facial, trigeminal, hypoglossal and recurrent nerve have been described. Although not being a typical transient nerve palsy, sensorineural hearing impairment of postnatal onset with progression beyond presbyacusis has been reported. Other uncommon presentations include recurrent short-term positional sensory symptoms, progressive sensorimotor mononeuropathy of the peroneal nerve, chronic sensory polyneuropathy, chronic sensorimotor polyneuropathy and subacute peripheral quadriparetic episodes (initial diagnosis was chronic idiopathic demyelinating polyneuropathy). Also a Davidenkow phenotype (scapuloperoneal syndrome) is described.

40On clinical examination, besides muscle weakness, atrophy and/or sensory signs in the affected nerves, reduced or absent tendon reflexes, mostly the ankle jerks, can be noted. Pes cavus may be found in 4-47%. The symptoms from acute neuropathy usually disappear in days to weeks. Full recovery occurs in 50% of episodes. Remaining symptoms are rarely severe. Chronic motor deficits after nerve palsies are noted in 10% to 15%. Other chronic symptoms like cramps, paresthesias and exercise-induced myalgia have been described.

41There is large clinical variability between HNPP patients. At the mild end of the spectrum, patients can be clinically asymptomatic. In different studies the percentages of asymptomatic family members of index patients varied from 6% to 23%. At the severe end of the spectrum patients have residual symptoms after nerve palsies, which can mimic a CMT phenotype.

42Electrophysiological studies show a characteristic pattern. Essentially all HNPP patients, whether symptomatic or not show an increase in distal motor latencies, especially of the median and peroneal nerves. Most patients show focal motor slowing at entrapment sites, more commonly in the ulnar nerve at the elbow than in the peroneal nerve at the fibular head. In other segments, MCV is normal in most cases, but can be slightly reduced in some. Sensory nerve conduction velocities are often decreased and sensory nerve action potential amplitudes are often reduced.

43Nerve biopsy shows segmental de- and remyelination and varying large-fibre loss. Tomacula, which are massive redundancies or overfolding of layers of variable thickness in the myelin sheath, are the pathologic hallmark, but are not pathognomonic.

44Central nervous system white matter lesions have been reported in isolated patients and in several members of a large family with HNPP. A recent report on 15 HNPP patients described central nervous system involvement. Decreased white matter volume was found in 71%, with minimal, predominantly executive, cognitive disorders in 64%.

45An overview of the key features of HNPP is presented in Table 1.

Aetiology

46A 1.5 Mb deletion on chromosome 17p11.2 is found in approximately 85-90% of patients with clinical evidence of HNPP. Most of the CMT1A- or HNPP-associated rearrangements in 17p11.2 are recurrent and mediated by nonallelic homologous recombination, although rare cases of HNPP have deletions of different size but always including the PMP22 gene. HNPP is an autosomal dominant disease. The de novo rate is probably 20%. Rare cases have mutations in the PMP22 gene. These mutations often result in stop codons and thus give rise to a null allele.

47The gene dosage hypothesis is supported by the finding of decreased PMP22 protein and decreased PMP22 mRNA expression levels in HNPP patients that correlated with phenotype. It is hypothesized that the focal symptoms of HNPP are caused by reversible conduction block (defined by >50% reduction of CMAP amplitudes between distal and proximal sites of stimulation). Structural abnormalities at the node of Ranvier explain the changes in axonal excitability, and these abnormalities would predispose the nerves to conduction block when subjected to pressure or stretch. In a mouse model heterozygous for Pmp22, conduction block was more rapidly induced by mechanical compression on the nerve in comparison to normal nerves and recovery was slower. They found focal axonal constrictions within tomacula. Reduced axonal diameter raises resistance to action potential propagation and thus predisposes these axons to conduction block. When the nerve is compressed, it may cause even further thinning of axons.

Diagnosis (diagnostic criteria and algorithms) and diagnostic methods

48Guidelines for diagnosis of HNPP are proposed by Dubourg et al.. A clinical manifestation of acute, painless, recurrent peripheral nerve palsies is typical for HNPP. However, also with more uncommon presentations (see “clinical description”) HNPP should be considered. A family history consistent with autosomal dominant inheritance is often present, but is not a prerequisite considering the de novo rate of 20% and asymptomatic occurrence of the disease. Electrophysiology of HNPP patients helps in establishing the diagnosis. Sonography of nerves show nerve hypertrophy at entrapment sites, although not always significant.

49If HNPP is suspected, DNA testing for the deletion of the PMP22 gene, followed by sequencing of the PMP22 gene if no deletion is found, can confirm the diagnosis. Like in CMT1A, nerve biopsy is essentially obsolete.

Differential diagnosis

50Pressure palsies are commonly the result of acquired physical compression of peripheral nerves, mostly of the median nerve at the wrist (carpal tunnel syndrome), the peroneal nerve at the fibular head and the ulnar nerve at the elbow. Screening for HNPP in 50 patients with isolated carpal tunnel syndrome showed that none of the patients had the PMP22 deletion. The suspicion of HNPP should be higher if a patient suffers from more than one episode of compression neuropathy, if there is also an unexplained polyneuropathy present and if there is a family history of neuropathy. Mononeuropathies may also be caused by compression due to a tumour, bleeding or abscess. In case of a neuropathy of the brachial plexus with a positive family history hereditary neuralgic amyotrophy (HNA) is considered most commonly and can be associated with mutations in the SEPT9 gene. The nerve palsy in HNPP is painless, whereas the brachial plexopathy in HNA is preceded by severe pain. In case of a negative family history the sporadic form of HNA, idiopathic neuralgic amyotrophy, should be considered.

Genetic counselling and antenatal diagnosis

51HNPP is an autosomal dominantly inherited disorder. For general aspects see corresponding paragraphs in the CMT1A section. In our experience, predictive testing, prenatal testing and PGD are not commonly requested.

Management including treatment

52Treatment is currently symptomatic. Management during a pressure palsy may include transient bracing. If a pressure palsy is not transient but residual, the bracing may need to be permanent. Patients should be informed about avoiding activities that are risk factors for pressure palsies. These activities include prolonged sitting with legs crossed, occupations requiring repetitive movements of the wrist, prolonged leaning on elbows and rapid weight loss. Toxin or medication-induced worsening of pre-existing peripheral neuropathy is a generally known phenomenon. Vincristine, used in chemotherapy, has been reported to exacerbate HNPP. No systematic controlled study of surgical decompression of nerves has been done. Given the vulnerability of the peripheral nerves in patients with HNPP, surgery is generally considered unfavourable.

53Perspectives on future therapeutic developments are discussed in the "unresolved questions" section.

Prognosis

54No natural history studies of HNPP exist. The prognosis is therefore unsure. In a study addressing age associated changes in electrophysiology, a reduction in CMAP with increasing age at examination was observed in nerves vulnerable to entrapment. This nerve-specific CMAP reduction likely results from a history of repetitive focal compression of the nerve. It is however not mentioned how the CMAP reduction correlates with symptoms. Recovery from acute neuropathy is often complete, although it can take months and if chronic symptoms persist, they are usually mild. Residual symptoms after nerve palsies can resemble a CMT phenotype. Symptomatic individuals have the frustration and disability associated with recurrent pressure palsies. Life expectancy is normal.

Unresolved questions

55As for CMT1A, the phenotype is highly variable in HNPP, suggesting the presence of modifiers - genetic and/or external factors. So far none are identified.

56Treatment is still only symptomatic. To our knowledge no trials have been undertaken. As HNPP is caused by a decreased dosage of PMP22, increasing the gene dosage may be a therapeutic target, as decreasing the gene dosage is for CMT1A. Stimulation of the endogenous PMP22 by enhancing the regulatory elements of PMP22 might be one option. Another option is to introduce another copy of the PMP22 gene into the peripheral nerve by gene therapy. An obstacle is that increasing the dosage of PMP22 above a certain level will cause CMT1A.

PMP22 point mutations

57Point mutations in PMP22 are found in a minority of patients suspected to have CMT or HNPP and the phenotype may vary from mild HNPP to severe CMT1. Clinical overlap between CMT1 and HNPP is also described, for instance in patients with the frameshift mutation Gly94fsX222 (c.281_282insG). For all general issues considering CMT1A and HNPP, see previous sections.

58According to some classifications CMT caused by PMP22 mutations is also called CMT1A, while others consider this a separate disease entity called CMT1E. One could argue to classify CMT caused by PMP22 point mutations as a separate entity, because the genetic defect is different from CMT caused by PMP22 duplication. An extra argument for considering this a separate disease entity is that PMP22 point mutations can phenotypically lead to CMT as well as HNPP or even an overlap between the two phenotypes. In this perspective, HNPP due to PMP22 point mutations should also be seen as a separate entity from HNPP due to PMP22 deletion.

59Several types of PMP22 point mutations are described (missense, nonsense, frameshift and splice-site mutations). Controversy about the pathogenicity of the Thr118Met mutation exists. It is reported as a benign polymorphism, as an autosomal recessive inherited mutation or as an autosomal dominant mutation, with HNPP as phenotype. Very rare autosomal recessive neuropathy (CMT4), caused by homozygosity for point mutations in PMP22 has been reported.

Conclusions

60PMP22 related neuropathies are the most prevalent amongst the inherited neuropathies. Knowledge about clinical presentation of CMT1A and HNPP and the expanding possibilities of genetic testing is a prerequisite for all neurologists and geneticists dealing with inherited neuropathy patients. Research on therapy has so far largely focussed on CMT1A, because of its prevalence and the rationale of decreasing the gene dosage of PMP22 which could potentially reverse the phenotype. One should keep in mind that a PMP22 directed therapy can not be applied to all cases of CMT. Therefore the genetic subtyping of CMT is essential to select those cases that might be eligible for targeted treatment strategies, as soon as these treatments become available.

Abbreviations

61AD: Autosomal dominant; AR: Autosomal recessive; ARHGEF10: Rho guanine nucleotide exchange factor 10; CIDP: Chronic inflammatory demyelinating polyneuropathy; CMAP: Compound muscle action potential; CMT: Charcot-Marie-Tooth disease; CMT1: Charcot-Marie-Tooth disease type 1; CMT1A: Charcot-Marie-Tooth disease type 1A; CSA: Cross-sectional area; CTDP1: C-terminal domain of RNA polymerase II subunit A, phosphatase, subunit 1; DNA: Deoxyribonucleic acid; EGR2: Early growth response 2; FBLN5: Fibulin 5; FGD4: FYVE, RhoGEF and PH domain-containing protein 4; FIG4: FIG4 homolog of S. cerevisiae; GDAP1: Ganglioside-induced differentiation-associated protein 1; GJB1: Gap junction protein, beta 1; HK1: Hexokinase 1; HMSN Ia: Hereditary motor and sensory neuropathy type Ia; HMSN: Hereditary motor and sensory neuropathy; HNA: Hereditary neuralgic amyotrophy; HNPP: Hereditary neuropathy with liability to pressure palsies; LITAF: Lipopolysaccharide-induced tumor necrosis factor-alpha factor; Mb: Mega base pairs; MCV: Motor conduction velocity; MPZ: Myelin protein zero; MTMR2: Myotubularin-related protein 2; NDRG1: N-myc downstream-regulated gene 1; NEFL: Neurofilament protein, light polypeptide; NGS: Next generation sequencing; PGD: Pre-implantation genetic diagnosis; PMP22: Peripheral myelin protein 22; PRX: Periaxin; RNA: Ribonucleic acid; SBF1: SET-binding factor 1; SBF2: SET-binding factor 2; SH3TC2: SH3 domain and tetratricopeptide repeat domain 2; SNAP: Sensory nerve action potential; SURF1: Surfeit 1; WES: Whole exome sequencing.

Competing interests

62The authors declare that they have no competing interests.

Authors’ contributions

63BWvP: drafting of the manuscript. AJvdK: revising of the manuscript. KvS-Z: revising of the manuscript. CV: drafting the parts on electrophysiology and revising of the manuscript. FB: revising of the manuscript. MdV: initiator and revising of the manuscript. All authors read and approved the final manuscript.

References 189

1.
Dyck PJ Lambert EH Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathiesArch Neurol1968 18603618
Not in our library10.1001/archneur.1968.00470360025002
2.
Charcot JM Marie P Sur une forme particulière d’atrophie musculaire progressive, souvent familial, débutant par les pieds et les jambes et atteignant plus tard les mainsRev Méd Paris1886 697138
Not in our library
3.
Tooth HH The peroneal type of progressive muscular atrophy1886 London: Lewis HK
Not in our library
4.
Neuromuscular Home Pagehttp://neuromuscular.wustl.edu/time/hmsn.html
Not in our library
5.
Inherited Peripheral Neuropathies Mutation Databasehttp://www.molgen.ua.ac.be/cmtmutations/Mutations/Default.cfm
Not in our library
6.
Pareyson D Scaioli V Laura M Clinical and electrophysiological aspects of Charcot-Marie-Tooth diseaseNeuromolecular Med2006 8322
Not in our library10.1385/nmm:8:1-2:3
7.
Reilly MM Sorting out the inherited neuropathiesPract Neurol2007 793105
Not in our library
8.
Harding AE Thomas PK The clinical features of hereditary motor and sensory neuropathy types I and IIBrain1980 103259280
Not in our library10.1093/brain/103.2.259
9.
Nicholson G Myers S Intermediate forms of Charcot-Marie-Tooth neuropathy: a reviewNeuromolecular Med2006 8123130
Not in our library10.1385/nmm:8:1-2:123
10.
Davis CJ Bradley WG Madrid R The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classificationJ Genet Hum1978 26311349
Not in our library
11.
Rossi A Paradiso C Cioni R Rizzuto N Guazzi G Charcot-Marie-Tooth disease: study of a large kinship with an intermediate formJ Neurol1985 2329198
Not in our library10.1007/bf00313907
12.
Madrid R Bradley WG Davis CJ The peroneal muscular atrophy syndrome. Clinical, genetic, electrophysiological and nerve biopsy studies. Part 2. Observations on pathological changes in sural nerve biopsiesJ Neurol Sci1977 3291122
Not in our library10.1016/0022-510x(77)90042-9
13.
Rouger H LeGuern E Birouk N Gouider R Tardieu S Plassart E Gugenheim M Vallat JM Louboutin JP Bouche P Agid Y Brice A Charcot-Marie-Tooth disease with intermediate motor nerve conduction velocities: characterization of 14 Cx32 mutations in 35 familiesHum Mutat1997 10443452
Not in our library10.1002/(sici)1098-1004(1997)10:6<443::aid-humu5>3.0.co;2-e
14.
Gabreels-Festen AA Gabreels FJ Jennekens FG Hereditary motor and sensory neuropathies. Present status of types I, II and IIIClin Neurol Neurosurg1993 9593107
Not in our library10.1016/0303-8467(93)90002-x
15.
Raeymaekers P Timmerman V Nelis E De Jonghe P Hoogendijk JE Baas F Barker DF Martin JJ De Visser M Bolhuis PA Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research GroupNeuromuscul Disord1991 19397
Not in our library10.1016/0960-8966(91)90055-w
16.
Lupski JR De Oca-Luna RM Slaugenhaupt S Pentao L Guzzetta V Trask BJ Saucedo-Cardenas O Barker DF Killian JM Garcia CA Chakravarti A Patel PI DNA duplication associated with Charcot-Marie-Tooth disease type 1ACell1991 66219232
Not in our library10.1016/0092-8674(91)90613-4
17.
Patel PI Roa BB Welcher AA Schoener-Scott R Trask BJ Pentao L Snipes GJ Garcia CA Francke U Shooter EM Lupski JR Suter U The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1ANat Genet1992 1159165
Not in our library10.1038/ng0692-159
18.
Timmerman V Nelis E Van Hul W Nieuwenhuijsen BW Chen KL Wang S Ben Othman K Cullen B Leach RJ Hanemann CO De Jonghe P Raeymaekers P Van Ommen GJB Martin JJ Müller HW Vance JM Fischbeck KH Van Broeckhoven C The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication [published erratum appears in Nat Genet 1992 Sep;2(1):84]Nat Genet1992 1171175
Not in our library10.1038/ng0692-171
19.
Valentijn LJ Bolhuis PA Zorn I Hoogendijk JE van den Bosch N Hensels GW Stanton VP Jr Housman DE Fischbeck KH Ross DA Nicholson GA Meershoek EJ Dauwerse HG Van Ommen GJB Baas F The peripheral myelin gene PMP-22/GAS-3 is duplicated in Charcot- Marie-Tooth disease type 1ANat Genet1992 1166170
Not in our library10.1038/ng0692-166
20.
Matsunami N Smith B Ballard L Lensch MW Robertson M Albertsen H Hanemann CO Muller HW Bird TD White R Chance PF Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1ANat Genet1992 1176179
Not in our library10.1038/ng0692-176
21.
Skre H Genetic and clinical aspects of Charcot-Marie-Tooth’s diseaseClin Genet1974 698118
Not in our library10.1111/j.1399-0004.1974.tb00638.x
22.
Braathen GJ Sand JC Lobato A Hoyer H Russell MB Genetic epidemiology of Charcot-Marie-Tooth in the general populationEur J Neurol2011 183948
Not in our library10.1111/j.1468-1331.2010.03037.x
23.
Foley C Schofield I Eglon G Bailey G Chinnery PF Horvath R Charcot-Marie-Tooth disease in Northern EnglandJ Neurol Neurosurg Psychiatry2012 83572573
Not in our library10.1136/jnnp-2011-300285
24.
Nicolaou P Zamba-Papanicolaou E Koutsou P Kleopa KA Georghiou A Hadjigeorgiou G Papadimitriou A Kyriakides T Christodoulou K Charcot-Marie-Tooth disease in Cyprus: epidemiological, clinical and genetic characteristicsNeuroepidemiology2010 35171177
Not in our library10.1159/000314351
25.
Karadima G Floroskufi P Koutsis G Vassilopoulos D Panas M Mutational analysis of PMP22, GJB1 and MPZ in Greek Charcot-Marie-Tooth type 1 neuropathy patientsClin Genet2011 80497499
Not in our library10.1111/j.1399-0004.2011.01657.x
26.
Thomas PK Marques W Jr Davis MB Sweeney MG King RH Bradley JL Muddle JR Tyson J Malcolm S Harding AE The phenotypic manifestations of chromosome 17p11.2 duplicationBrain1997 1203465478
Not in our library10.1093/brain/120.3.465
27.
Birouk N Gouider R Le Guern E Gugenheim M Tardieu S Maisonobe T Le Forestier N Agid Y Brice A Bouche P Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 casesBrain1997 120813823
Not in our library10.1093/brain/120.5.813
28.
Marques W Jr Freitas MR Nascimento OJ Oliveira AB Calia L Melo A Lucena R Rocha V Barreira AA 17p duplicated Charcot-Marie-Tooth 1A Characteristics of a new populationJ Neurol2005 252972979
Not in our library10.1007/s00415-005-0797-9
29.
Bienfait HM Verhamme C Van Schaik IN Koelman JH De Visser BW De Haan RJ Baas F Van Engelen BG De Visser M Comparison of CMT1A and CMT2: similarities and differencesJ Neurol2006 25315721580
Not in our library10.1007/s00415-006-0260-6
30.
Berciano J Garcia A Combarros O Initial semeiology in children with Charcot-Marie-Tooth disease 1A duplicationMuscle Nerve2003 273439
Not in our library10.1002/mus.10299
31.
Baets J Deconinck T De Vriendt E Zimon M Yperzeele L Van Hoorenbeeck K Peeters K Spiegel R Parman Y Ceulemans B Van Bogaert P Pou-Serradell A Bernea G Dinopoulos A Auer-Grumbach M Sallinen SL Fabrizi GM Pauly F Van den Bergh P Bilir B Battaloglu E Madrid RE Kabzinska D Kochanski A Topaloglu H Miller G Jordanova A Timmerman V De Jonghe P Genetic spectrum of hereditary neuropathies with onset in the first year of lifeBrain2011 13426642676
Not in our library10.1093/brain/awr184
32.
Abe Y Ikegami T Hayasaka K Tanno Y Watanabe T Sugiyama Y Yamamoto T Pressure palsy as the initial presentation in a case of late-onset Charcot-Marie-Tooth disease type 1AIntern Med1997 36501503
Not in our library10.2169/internalmedicine.36.501
33.
Lupski JR Chance PF Dyck PJ, Thomas PKHereditary Motor and Sensory Neuropathies Involving Altered Dosage or Mutation of PMP22: The CMT1A Duplication and HNPP DeletionPeripheral Neuropathy2005 FourthPhiladelphia: Elsevier Saunders16591680
Not in our library
34.
Hoogendijk JE De Visser M Bolhuis PA Hart AA Ongerboer de Visser BW Hereditary motor and sensory neuropathy type I: clinical and neurographical features of the 17p duplication subtypeMuscle Nerve1994 178590
Not in our library10.1002/mus.880170112
35.
Verhamme C Van Schaik IN Koelman JHTM De Haan RJ De Visser M The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up studyBrain2009 13232523262
Not in our library10.1093/brain/awp251
36.
Videler AJ Beelen A Van Schaik IN De Visser M Nollet F Manual dexterity in hereditary motor and sensory neuropathy type 1a: severity of limitations and feasibility and reliability of two assessment instrumentsJ Rehabil Med2008 40132136
Not in our library10.2340/16501977-0143
37.
Shy ME Lupski JR Chance PF Klein CJ Dyck PJ Dyck PJ, Thomas PKHereditary Motor and Sensory Neuropathies: An overview of Clinical, Genetic, Electrophysiologic, and Pathologic FeaturesPeripheral Neuropathy2005 FourthPhiladelphia: Elsevier Saunders16231658
Not in our library
38.
Verhamme C Van Schaik IN Koelman JHTM De Haan RJ Vermeulen M De Visser M Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy IaJ Neurol2004 25114911497
Not in our library10.1007/s00415-004-0578-x
39.
Ribiere C Bernardin M Sacconi S Delmont E Fournier-Mehouas M Rauscent H Benchortane M Staccini P Lanteri-Minet M Desnuelle C Pain assessment in Charcot-Marie-Tooth (CMT) diseaseAnn Phys Rehabil Med2012 55160173
Not in our library10.1016/j.rehab.2012.02.005
40.
Gemignani F Melli G Alfieri S Inglese C Marbini A Sensory manifestations in Charcot-Marie-Tooth diseaseJ Peripher Nerv Syst2004 9714
Not in our library10.1111/j.1085-9489.2004.09103.x
41.
Kalkman JS Schillings ML van der Werf SP Padberg GW Zwarts MJ Van Engelen BG Bleijenberg G Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-IJ Neurol Neurosurg Psychiatry2005 7614061409
Not in our library10.1136/jnnp.2004.050005
42.
Jagersma E Jeukens-Visser M Van Paassen BW Meester-Delver A Nollet F Severe Fatigue and Reduced Quality of Life in Children With Hereditary Motor and Sensory Neuropathy 1AJ Child Neurol2013 28429434
Not in our library10.1177/0883073812447681
43.
Auer-Grumbach M Strasser-Fuchs S Wagner K Korner E Fazekas F Roussy-Levy syndrome is a phenotypic variant of Charcot-Marie-Tooth syndrome IA associated with a duplication on chromosome 17p11.2J Neurol Sci1998 1547275
Not in our library10.1016/s0022-510x(97)00218-9
44.
Carvalho AA Vital A Ferrer X Latour P Lagueny A Brechenmacher C Vital C Charcot-Marie-Tooth disease type 1A: clinicopathological correlations in 24 patientsJ Peripher Nerv Syst2005 108592
Not in our library10.1111/j.1085-9489.2005.10112.x
45.
Plante-Bordeneuve V Guiochon-Mantel A Lacroix C Lapresle J Said G The Roussy-Levy family: from the original description to the geneAnn Neurol1999 46770773
Not in our library10.1002/1531-8249(199911)46:5<770::aid-ana13>3.0.co;2-u
46.
Verhagen WI Huygen PL Gabreels-Festen AA Engelhart M Van Mierlo PJ Van Engelen BG Sensorineural hearing impairment in patients with Pmp22 duplication, deletion, and frameshift mutationsOtol Neurotol2005 26405414
Not in our library10.1097/01.mao.0000169769.93173.df
47.
Rance G Ryan MM Bayliss K Gill K O’Sullivan C Whitechurch M Auditory function in children with Charcot-Marie-Tooth diseaseBrain2012 13514121422
Not in our library10.1093/brain/aws085
48.
Poretti A Palla A Tarnutzer AA Petersen JA Weber KP Straumann D Jung HH Vestibular impairment in patients with Charcot-Marie-tooth diseaseNeurology2013 8020992105
Not in our library10.1212/wnl.0b013e318295d72a
49.
Boentert M Knop K Schuhmacher C Gess B Okegwo A Young P Sleep disorders in Charcot-Marie-Tooth disease type 1J Neurol Neurosurg Psychiatry2014 85319325
Not in our library10.1136/jnnp-2013-305296
50.
Martinoli C Schenone A Bianchi S Mandich P Caponetto C Abbruzzese M Derchi LE Sonography of the median nerve in Charcot-Marie-Tooth diseaseAJR Am J Roentgenol2002 17815531556
Not in our library10.2214/ajr.178.6.1781553
51.
Sinclair CD Miranda MA Cowley P Morrow JM Davagnanam I Mehta H Hanna MG Koltzenburg M Reilly MM Yousry TA Thornton JS MRI shows increased sciatic nerve cross sectional area in inherited and inflammatory neuropathiesJ Neurol Neurosurg Psychiatry2011 8212831286
Not in our library10.1136/jnnp.2010.211334
52.
Schreiber S Oldag A Kornblum C Kollewe K Kropf S Schoenfeld A Feistner H Jakubiczka S Kunz WS Scherlach C Tempelmann C Mawrin C Dengler R Schreiber F Goertler M Vielhaber S Sonography of the median nerve in CMT1A, CMT2A, CMTX, and HNPPMuscle Nerve2013 47385395
Not in our library10.1002/mus.23681
53.
Zaidman CM Al-Lozi M Pestronk A Peripheral nerve size in normals and patients with polyneuropathy: an ultrasound studyMuscle Nerve2009 40960966
Not in our library10.1002/mus.21431
54.
Kaku DA Parry GJ Malamut R Lupski JR Garcia CA Nerve conduction studies in Charcot-Marie-Tooth polyneuropathy associated with a segmental duplication of chromosome 17Neurology1806–1808 199343
Not in our library10.1212/wnl.43.9.1806
55.
Garcia CA Malamut RE England JD Parry GS Liu P Lupski JR Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplicationNeurology2090–2093 199545
Not in our library10.1212/wnl.45.11.2090
56.
Silander K Meretoja P Nelis E Timmerman V Van Broeckhoven C Aula P Savontaus ML A de novo duplication in 17p11.2 and a novel mutation in the Po gene in two Dejerine-Sottas syndrome patientsHum Mutat1996 8304310
Not in our library10.1002/(sici)1098-1004(1996)8:4<304::aid-humu2>3.0.co;2-7
57.
Plante-Bordeneuve V Parman Y Guiochon-Mantel A Alj Y Deymeer F Serdaroglu P Eraksoy M Said G The range of chronic demyelinating neuropathy of infancy: a clinico- pathological and genetic study of 15 unrelated casesJ Neurol2001 248795803
Not in our library10.1007/s004150170096
58.
Meggouh F De Visser M Arts WF De Coo RI Van Schaik IN Baas F Early onset neuropathy in a compound form of Charcot-Marie-Tooth diseaseAnn Neurol2005 57589591
Not in our library10.1002/ana.20434
59.
Hodapp JA Carter GT Lipe HP Michelson SJ Kraft GH Bird TD Double trouble in hereditary neuropathy: concomitant mutations in the PMP-22 gene and another gene produce novel phenotypesArch Neurol2006 63112117
Not in our library10.1001/archneur.63.1.112
60.
Chanson JB Echaniz-Laguna A Blanc F Lacour A Ballonzoli L Kremer S Namer IJ Lannes B Tranchant C Vermersch P De Seze J Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective studyJ Neurol Neurosurg Psychiatry2013 84392397
Not in our library10.1136/jnnp-2012-303725
61.
Uncini A Di Guglielmo G Di Muzio A Gambi D Sabatelli M Mignogna T Tonali P Marzella R Finelli P Archidiacono N Rocchi M Differential electrophysiological features of neuropathies associated with 17p11.2 deletion and duplicationMuscle Nerve1995 18628635
Not in our library10.1002/mus.880180610
62.
Lewis RA Krajewski K Tate B Shy ME Motor Unit Number Estimation (MUNE) of Proximal and Distal Extremity Muscles in CMT1A, CMTX, and CMT2Neurology2000 54Suppl 3A70
Not in our library
63.
Gabreels-Festen AA Bolhuis PA Hoogendijk JE Valentijn LJ Eshuis EJ Gabreels FJ Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutationsActa Neuropathol1995 90645649
Not in our library10.1007/bf00318579
64.
Fabrizi GM Simonati A Morbin M Cavallaro T Taioli F Benedetti MD Edomi P Rizzuto N Clinical and pathological correlations in Charcot-Marie-Tooth neuropathy type 1A with the 17p11.2p12 duplication: a cross- sectional morphometric and immunohistochemical study in twenty casesMuscle Nerve1998 21869877
Not in our library10.1002/(sici)1097-4598(199807)21:7<869::aid-mus4>3.0.co;2-4
65.
Gabreels-Festen AA Joosten EM Gabreels FJ Jennekens FG Janssen-van Kempen TW Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN type I)J Neurol Sci1992 107145154
Not in our library10.1016/0022-510x(92)90282-p
66.
Smith TW Bhawan J Keller RB DeGirolami U Charcot-Marie-Tooth disease associated with hypertrophic neuropathy: a neuropathologic study of two casesJ Neuropathol Exp Neurol1980 39420440
Not in our library10.1097/00005072-198007000-00003
67.
Valentijn LJ Baas F Zorn I Hensels GW De Visser M Bolhuis PA Alternatively sized duplication in Charcot-Marie-Tooth disease type 1AHum Mol Genet1993 221432146
Not in our library10.1093/hmg/2.12.2143
68.
Zhang F Seeman P Liu P Weterman MA Gonzaga-Jauregui C Towne CF Batish SD De Vriendt E De Jonghe P Rautenstrauss B Krause KH Khajavi M Posadka J Vandenberghe A Palau F Van Maldergem L Baas F Timmerman V Lupski JR Mechanisms for nonrecurrent genomic rearrangements associated with CMT1A or HNPP: rare CNVs as a cause for missing heritabilityAm J Hum Genet2010 86892903
Not in our library10.1016/j.ajhg.2010.05.001
69.
Weterman MA Van Ruissen F De Wissel M Bordewijk L Samijn JP van der Pol WL Meggouh F Baas F Copy number variation upstream of PMP22 in Charcot-Marie-Tooth diseaseEur J Hum Genet2010 18421428
Not in our library10.1038/ejhg.2009.186
70.
Valentijn LJ Baas F Wolterman RA Hoogendijk JE van den Bosch NHA Zorn I Gabreëls-Festen AAWM De Visser M Bolhuis PA Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1ANat Genet1992 2288291
Not in our library10.1038/ng1292-288
71.
Gabriel JM Erne B Pareyson D Sghirlanzoni A Taroni F Steck AJ Gene dosage effects in hereditary peripheral neuropathy. Expression of peripheral myelin protein 22 in Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies nerve biopsiesNeurology1997 4916351640
Not in our library10.1212/wnl.49.6.1635
72.
Yoshikawa H Nishimura T Nakatsuji Y Fujimura H Himoro M Hayasaka K Sakoda S Yanagihara T Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with Charcot- Marie-Tooth disease type 1AAnn Neurol1994 35445450
Not in our library10.1002/ana.410350412
73.
Snipes GJ Suter U Welcher AA Shooter EM Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13)J Cell Biol1992 117225238
Not in our library10.1083/jcb.117.1.225
74.
Krajewski KM Lewis RA Fuerst DR Turansky C Hinderer SR Garbern J Kamholz J Shy ME Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1ABrain2000 12315161527
Not in our library10.1093/brain/123.7.1516
75.
Hattori N Yamamoto M Yoshihara T Koike H Nakagawa M Yoshikawa H Ohnishi A Hayasaka K Onodera O Baba M Yasuda H Saito T Nakashima K Kira J Kaji R Oka N Sobue G Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patientsBrain2003 126134151
Not in our library10.1093/brain/awg012
76.
Robaglia-Schlupp A Pizant J Norreel JC Passage E Saberan-Djoneidi D Ansaldi JL Vinay L Figarella-Branger D Levy N Clarac F Cau P Pellissier JF Fontés M PMP22 overexpression causes dysmyelination in miceBrain2002 12522132221
Not in our library10.1093/brain/awf230
77.
Yiu EM Burns J Ryan MM Ouvrier RA Neurophysiologic abnormalities in children with Charcot-Marie-Tooth disease type 1AJ Peripher Nerv Syst2008 13236241
Not in our library10.1111/j.1529-8027.2008.00182.x
78.
Saporta MA Katona I Lewis RA Masse S Shy ME Li J Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1ABrain2009 13232633273
Not in our library10.1093/brain/awp274
79.
Verhamme C King RH Ten Asbroek AL Muddle JR Nourallah M Wolterman R Baas F Van Schaik IN Myelin and axon pathology in a long-term study of PMP22-overexpressing miceJ Neuropathol Exp Neurol2011 70386398
Not in our library10.1097/nen.0b013e318217eba0
80.
Hoogendijk JE Hensels GW Gabreels-Festen AA Gabreels FJ Janssen EA De Jonghe P Martin JJ Van Broeckhoven C Valentijn LJ Baas F De Visser M Bolhuis PA De-novo mutation in hereditary motor and sensory neuropathy type ILancet1992 33910811082
Not in our library10.1016/0140-6736(92)90668-s
81.
Blair IP Nash J Gordon MJ Nicholson GA Prevalence and origin of de novo duplications in Charcot-Marie-Tooth disease type 1A: first report of a de novo duplication with a maternal originAm J Hum Genet1996 58472476
Not in our library
82.
Genetics of Charcot-Marie-Tooth (CMT) Disease within the Frame of the Human Genome Project Success · 2014
No notice
83.
Rossor AM Polke JM Houlden H Reilly MM Clinical implications of genetic advances in Charcot-Marie-Tooth diseaseNat Rev Neurol2013 9562571
Not in our library10.1038/nrneurol.2013.179
84.
Azzedine H Senderek J Rivolta C Chrast R Molecular genetics of charcot-marie-tooth disease: from genes to genomesMol Syndromol2012 3204214
Not in our library10.1159/000343487
85.
Gieselmann V Krageloh-Mann I Metachromatic leukodystrophy–an updateNeuropediatrics2010 4116
Not in our library10.1055/s-0030-1253412
86.
Jansen GA Waterham HR Wanders RJ Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7)Hum Mutat2004 23209218
Not in our library10.1002/humu.10315
87.
Siddiqi ZA Sanders DB Massey JM Peripheral neuropathy in Krabbe disease: electrodiagnostic findingsNeurology2006 67263267
Not in our library10.1212/01.wnl.0000230153.34613.84
88.
X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management · 2012
No notice
89.
Uhlenberg B Schuelke M Ruschendorf F Ruf N Kaindl AM Henneke M Thiele H Stoltenburg-Didinger G Aksu F Topaloglu H Nurnberg P Hubner C Weschke B Gartner J Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like diseaseAm J Hum Genet2004 75251260
Not in our library10.1086/422763
90.
Lowe syndrome · 2006
No notice
91.
Latov N Biomarkers of CIDP in patients with diabetes or CMT1J Peripher Nerv Syst2011 16Suppl 11417
Not in our library10.1111/j.1529-8027.2011.00299.x
92.
Pareyson D Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathiesNeurol Sci2004 257282
Not in our library10.1007/s10072-004-0233-4
93.
Gabreels-Festen AA Gabreels FJ Hoogendijk JE Bolhuis PA Jongen PJ Vingerhoets HM Chronic inflammatory demyelinating polyneuropathy or hereditary motor and sensory neuropathy? Diagnostic value of morphological criteriaActa Neuropathol1993 86630635
Not in our library10.1007/bf00294303
94.
Said G Diabetic neuropathy–a reviewNat Clin Pract Neurol2007 3331340
Not in our library10.1038/ncpneuro0504
95.
Said G Bigo A Ameri A Gayno JP Elgrably F Chanson P Slama G Uncommon early-onset neuropathy in diabetic patientsJ Neurol1998 2456168
Not in our library10.1007/s004150050179
96.
Fusco C Frattini D Scarano A Giustina ED Congenital pes cavus in a Charcot-Marie-tooth disease type 1A newbornPediatr Neurol2009 40461464
Not in our library10.1016/j.pediatrneurol.2008.12.010
97.
Steiner I Gotkine M Steiner-Birmanns B Biran I Silverstein S Abeliovich D Argov Z Wirguin I Increased severity over generations of Charcot-Marie-Tooth disease type 1AJ Neurol2008 255813819
Not in our library10.1007/s00415-008-0693-1
98.
Dupre N Bouchard JP Cossette L Brunet D Vanasse M Lemieux B Mathon G Puymirat J Clinical and electrophysiological study in French-Canadian population with Charcot-Marie-tooth disease type 1A associated with 17p11.2 duplicationCan J Neurol Sci1999 26196200
Not in our library10.1017/s031716710000024x
99.
Bird TD Pagon RA, Adam MP, Bird TDCharcot-Marie-Tooth Neuropathy Type 1GeneReviews™ [Internet]1993 Seattle: University of Washington, Seattle2014
Not in our library
100.
Borry P Evers-Kiebooms G Cornel MC Clarke A Dierickx K Genetic testing in asymptomatic minors: background considerations towards ESHG RecommendationsEur J Hum Genet2009 17711719
Not in our library10.1038/ejhg.2009.25
101.
American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of DirectorsPoints to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescentsAm J Hum Genet1995 5712331241
Not in our library
102.
Bernard R Boyer A Negre P Malzac P Latour P Vandenberghe A Philip N Levy N Prenatal detection of the 17p11.2 duplication in Charcot-Marie-Tooth disease type 1A: necessity of a multidisciplinary approach for heterogeneous disordersEur J Hum Genet2002 10297302
Not in our library10.1038/sj.ejhg.5200804
103.
Goossens V Traeger-Synodinos J Coonen E De Rycke M Moutou C Pehlivan T Derks-Smeets IA Harton G ESHRE PGD Consortium data collection XI: cycles from January to December 2008 with pregnancy follow-up to October 2009Hum Reprod1887–1911 201227
Not in our library10.1093/humrep/des106
104.
Harper JC Wilton L Traeger-Synodinos J Goossens V Moutou C SenGupta SB Pehlivan Budak T Renwick P De Rycke M Geraedts JP Harton G The ESHRE PGD Consortium: 10 years of data collectionHum Reprod Update2012 18234247
Not in our library10.1093/humupd/dmr052
105.
Young P De Jonghe P Stogbauer F Butterfass-Bahloul T Treatment for Charcot-Marie-Tooth diseaseCochrane Database Syst Rev2008 1CD006052
Not in our library10.1002/14651858.cd006052.pub2
106.
Sackley C Disler PB Turner-Stokes L Wade DT Brittle N Hoppitt T Rehabilitation interventions for foot drop in neuromuscular diseaseCochrane Database Syst Rev2009 3CD003908
Not in our library10.1002/14651858.cd003908.pub3
107.
Guyton GP Mann RA The pathogenesis and surgical management of foot deformity in Charcot-Marie-Tooth diseaseFoot Ankle Clin2000 5317326
Not in our library
108.
Ward CM Dolan LA Bennett DL Morcuende JA Cooper RR Long-term results of reconstruction for treatment of a flexible cavovarus foot in Charcot-Marie-Tooth diseaseJ Bone Joint Surg Am2008 9026312642
Not in our library10.2106/jbjs.g.01356
109.
Leeuwesteijn AE De Visser E Louwerens JW Flexible cavovarus feet in Charcot-Marie-Tooth disease treated with first ray proximal dorsiflexion osteotomy combined with soft tissue surgery: a short-term to mid-term outcome studyFoot Ankle Surg2010 16142147
Not in our library10.1016/j.fas.2009.10.002
110.
Videler A Eijffinger E Nollet F Beelen A A thumb opposition splint to improve manual dexterity and upper-limb functioning in Charcot-Marie-Tooth diseaseJ Rehabil Med2012 44249253
Not in our library10.2340/16501977-0932
111.
Wood VE Huene D Nguyen J Treatment of the upper limb in Charcot-Marie-Tooth diseaseJ Hand Surg [Br ]1995 20511518
Not in our library10.1016/s0266-7681(05)80166-4
112.
Brown RE Zamboni WA Zook EG Russell RC Evaluation and management of upper extremity neuropathies in Charcot- Marie-Tooth diseaseJ Hand Surg [Am ]1992 17523530
Not in our library10.1016/0363-5023(92)90366-w
113.
Sheth S Francies K Siskind CE Feely SM Lewis RA Shy ME Diabetes mellitus exacerbates motor and sensory impairment in CMT1AJ Peripher Nerv Syst2008 13299304
Not in our library10.1111/j.1529-8027.2008.00196.x
114.
Ursino G Alberti MA Grandis M Reni L Pareyson D Bellone E Gemelli C Sabatelli M Pisciotta C Luigetti M Santoro L Massollo L Schenone A Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1ANeuromuscul Disord2013 23902906
Not in our library10.1016/j.nmd.2013.07.002
115.
Weimer LH Podwall D Medication-induced exacerbation of neuropathy in Charcot Marie Tooth diseaseJ Neurol Sci2006 2424754
Not in our library10.1016/j.jns.2005.11.014
116.
Graf WD Chance PF Lensch MW Eng LJ Lipe HP Bird TD Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1ACancer1996 7713561362
Not in our library10.1002/(sici)1097-0142(19960401)77:7<1356::aid-cncr20>3.0.co;2-#
117.
Hildebrandt G Holler E Woenkhaus M Quarch G Reichle A Schalke B Andreesen R Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapyAnn Oncol2000 11743747
Not in our library10.1023/a:1008369315240
118.
Shy ME Chen L Swan ER Taube R Krajewski KM Herrmann D Lewis RA McDermott MP Neuropathy progression in Charcot-Marie-Tooth disease type 1ANeurology2008 70378383
Not in our library10.1212/01.wnl.0000297553.36441.ce
119.
Garcia A Combarros O Calleja J Berciano J Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhood: a longitudinal clinical and electrophysiologic studyNeurology1998 5010611067
Not in our library10.1212/wnl.50.4.1061
120.
Padua L Pareyson D Aprile I Cavallaro T Quattrone A Rizzuto N Vita G Tonali P Schenone A Natural history of CMT1A including QoL: A 2-year prospective studyNeuromuscul Disord2008 18199203
Not in our library10.1016/j.nmd.2007.11.008
121.
Manfioletti G Ruaro ME Del Sal G Philipson L Schneider C A growth arrest-specific (gas) gene codes for a membrane proteinMol Cell Biol1990 1029242930
Not in our library10.1128/mcb.10.6.2924-2930.1990
122.
Choi BO Koo SK Park MH Rhee H Yang SJ Choi KG Jung SC Kim HS Hyun YS Nakhro K Lee HJ Woo HM Chung KW Exome sequencing is an efficient tool for genetic screening of Charcot-Marie-Tooth diseaseHum Mutat2012 3316101615
Not in our library10.1002/humu.22143
123.
Kohl B Groh J Wessig C Wiendl H Kroner A Martini R Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1ANeurobiol Dis2010 387884
Not in our library10.1016/j.nbd.2010.01.001
124.
Kohl B Fischer S Groh J Wessig C Martini R MCP-1/CCL2 Modifies Axon Properties in a PMP22-Overexpressing Mouse Model for Charcot-Marie-Tooth 1A NeuropathyAm J Pathol2010 17613901399
Not in our library10.2353/ajpath.2010.090694
125.
Ramaglia V Tannemaat MR De Kok M Wolterman R Vigar MA King RH Morgan BP Baas F Complement inhibition accelerates regeneration in a model of peripheral nerve injuryMol Immunol2009 47302309
Not in our library10.1016/j.molimm.2009.09.019
126.
Ramaglia V Wolterman R De Kok M Vigar MA Wagenaar-Bos I King RH Morgan BP Baas F Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injuryAm J Pathol2008 17210431052
Not in our library10.2353/ajpath.2008.070660
127.
Sereda MW Meyer Zu Horste G Suter U Uzma N Nave KA Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)Nat Med2003 915331537
Not in our library10.1038/nm957
128.
Meyer Zu Horste G Prukop T Liebetanz D Mobius W Nave KA Sereda MW Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathyAnn Neurol2007 616172
Not in our library10.1002/ana.21026
129.
Passage E Norreel JC Noack-Fraissignes P Sanguedolce V Pizant J Thirion X Robaglia-Schlupp A Pellissier JF Fontes M Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth diseaseNat Med2004 10396401
Not in our library10.1038/nm1023
130.
Verhamme C De Haan RJ Vermeulen M Baas F De Visser M Van Schaik IN Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trialBMC Med2009 770
Not in our library10.1186/1741-7015-7-70
131.
Micallef J Attarian S Dubourg O Gonnaud PM Hogrel JY Stojkovic T Bernard R Jouve E Pitel S Vacherot F Remec JF Jomir L Azabou E Al-Moussawi M Lefebvre MN Attolini L Yaici S Tanesse D Fontes M Pouget J Blin O Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trialLancet Neurol2009 811031110
Not in our library10.1016/s1474-4422(09)70260-1
132.
Burns J Ouvrier RA Yiu EM Joseph PD Kornberg AJ Fahey MC Ryan MM Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trialLancet Neurol2009 8537544
Not in our library10.1016/s1474-4422(09)70108-5
133.
Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial · 2011
No notice
134.
Burns J Ouvrier RA Yiu EM Ryan MM Extended treatment of childhood Charcot-Marie-Tooth disease with high-dose ascorbic acidJ Peripher Nerv Syst2011 16272274
Not in our library10.1111/j.1529-8027.2011.00348.x
135.
Robertson JF Willsher PC Winterbottom L Blamey RW Thorpe S Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancerEur J Cancer1999 35214218
Not in our library10.1016/s0959-8049(98)00388-8
136.
Sahenk Z Nagaraja HN McCracken BS King WM Freimer ML Cedarbaum JM Mendell JR NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patientsNeurology2005 65681689
Not in our library10.1212/01.wnl.0000171978.70849.c5
137.
Sahenk Z Galloway G Clark KR Malik V Rodino-Klapac LR Kaspar BK Chen L Braganza C Montgomery C Mendell JR AAV1.NT-3 Gene Therapy for Charcot-Marie-Tooth NeuropathyMol Ther2014 22511521
Not in our library10.1038/mt.2013.250
138.
Orfali W Nicholson RN Guiot MC Peterson AC Snipes GJ An 8.5-kb segment of the PMP22 promoter responds to loss of axon signals during Wallerian degeneration, but does not respond to specific axonal signals during nerve regenerationJ Neurosci Res2005 803746
Not in our library10.1002/jnr.20425
139.
Jones EA Lopez-Anido C Srinivasan R Krueger C Chang LW Nagarajan R Svaren J Regulation of the PMP22 gene through an intronic enhancerJ Neurosci2011 3142424250
Not in our library10.1523/jneurosci.5893-10.2011
140.
Jang SW Lopez-Anido C MacArthur R Svaren J Inglese J Identification of drug modulators targeting gene-dosage disease CMT1AACS Chem Biol2012 712051213
Not in our library10.1021/cb300048d
141.
Sereda M Griffiths I Puhlhofer A Stewart H Rossner MJ Zimmerman F Magyar JP Schneider A Hund E Meinck HM Suter U Nave KA A transgenic rat model of Charcot-Marie-Tooth diseaseNeuron1996 1610491060
Not in our library10.1016/s0896-6273(00)80128-2
142.
De Visser M Verhamme C Ascorbic acid for treatment in CMT1A: what’s next?Lancet Neurol2011 10291293
Not in our library10.1016/s1474-4422(11)70042-4
143.
Chance PF Alderson MK Leppig KA Lensch MW Matsunami N Smith B Swanson PD Odelberg SJ Disteche CM Bird TD DNA deletion associated with hereditary neuropathy with liability to pressure palsiesCell1993 72143151
Not in our library10.1016/0092-8674(93)90058-x
144.
Mouton P Tardieu S Gouider R Birouk N Maisonobe T Dubourg O Brice A LeGuern E Bouche P Spectrum of clinical and electrophysiologic features in HNPP patients with the 17p11.2 deletionNeurology1999 5214401446
Not in our library10.1212/wnl.52.7.1440
145.
Meretoja P Silander K Kalimo H Aula P Meretoja A Savontaus ML Epidemiology of hereditary neuropathy with liability to pressure palsies (HNPP) in south western FinlandNeuromuscul Disord1997 7529532
Not in our library10.1016/s0960-8966(97)00100-4
146.
Chance PF Inherited focal, episodic neuropathies: hereditary neuropathy with liability to pressure palsies and hereditary neuralgic amyotrophyNeuromolecular Med2006 8159174
Not in our library10.1385/nmm:8:1:159
147.
Gouider R LeGuern E Gugenheim M Tardieu S Maisonobe T Leger JM Vallat JM Agid Y Bouche P Brice A Clinical, electrophysiologic, and molecular correlations in 13 families with hereditary neuropathy with liability to pressure palsies and a chromosome 17p11.2 deletionNeurology1995 4520182023
Not in our library10.1212/wnl.45.11.2018
148.
Lenssen PP Gabreels-Festen AA Valentijn LJ Jongen PJ Van Beersum SE Van Engelen BG Van Wensen PJ Bolhuis PA Gabreels FJ Mariman EC Hereditary neuropathy with liability to pressure palsies. Phenotypic differences between patients with the common deletion and a PMP22 frame shift mutationBrain1998 121814511458
Not in our library10.1093/brain/121.8.1451
149.
Gabreels-Festen AA Gabreels FJ Joosten EM Vingerhoets HM Renier WO Hereditary neuropathy with liability to pressure palsies in childhoodNeuropediatrics1992 23138143
Not in our library10.1055/s-2008-1071329
150.
Pareyson D Scaioli V Taroni F Botti S Lorenzetti D Solari A Ciano C Sghirlanzoni A Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletionNeurology1996 4611331137
Not in our library10.1212/wnl.46.4.1133
151.
Koike H Hirayama M Yamamoto M Ito H Hattori N Umehara F Arimura K Ikeda S Ando Y Nakazato M Kaji R Hayasaka K Nakagawa M Sakoda S Matsumura K Onodera O Baba M Yasuda H Saito T Kira J Nakashima K Oka N Sobue G Age associated axonal features in HNPP with 17p11.2 deletion in JapanJ Neurol Neurosurg Psychiatry2005 7611091114
Not in our library10.1136/jnnp.2004.048140
152.
Li J Krajewski K Lewis RA Shy ME Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsiesMuscle Nerve2004 29205210
Not in our library10.1002/mus.10521
153.
Kim SM Chung KW Choi BO Yoon ES Choi JY Park KD Sunwoo IN Hereditary neuropathy with liability to pressure palsies (HNPP) patients of Korean ancestry with chromosome 17p11.2-p12 deletionExp Mol Med2004 362835
Not in our library10.1038/emm.2004.4
154.
Dubourg O Mouton P Brice A LeGuern E Bouche P Guidelines for diagnosis of hereditary neuropathy with liability to pressure palsiesNeuromuscul Disord2000 10206208
Not in our library10.1016/s0960-8966(99)00103-0
155.
Iwasaki Y Iguchi H Ikeda K Kano O CNS involvement in hereditary neuropathy with pressure palsies (HNPP)Neurology2046 200768
Not in our library10.1212/01.wnl.0000268588.67446.3e
156.
Poloni TE Merlo IM Alfonsi E Marinou-Aktipi K Botti S Arrigo A Taroni F Ceroni M Facial nerve is liable to pressure palsyNeurology1998 51320322
Not in our library10.1212/wnl.51.1.320
157.
Verhagen WI Gabreels-Festen AA Van Wensen PJ Joosten EM Vingerhoets HM Gabreels FJ De Graaf R Hereditary neuropathy with liability to pressure palsies: a clinical, electroneurophysiological and morphological studyJ Neurol Sci1993 116176184
Not in our library10.1016/0022-510x(93)90323-q
158.
Davies DM Recurrent peripheral nerve palsies in a familyLancet1954 267266268
Not in our library10.1016/s0140-6736(54)90193-2
159.
Winter WC Juel VC Hypoglossal neuropathy in hereditary neuropathy with liability to pressure palsyNeurology2003 6111541155
Not in our library10.1212/01.wnl.0000086808.56096.da
160.
Ohkoshi N Kohno Y Hayashi A Wada T Shoji S Acute vocal cord paralysis in hereditary neuropathy with liability to pressure palsiesNeurology2001 561415
Not in our library10.1212/wnl.56.10.1415
161.
Verma A Neuropathic scapuloperoneal syndrome (Davidenkow’s syndrome) with chromosome 17p11.2 deletionMuscle Nerve2005 32668671
Not in our library10.1002/mus.20402
162.
Bird TD Pagon RA, Adam MP, Bird TDHereditary Neuropathy with Liability to Pressure PalsiesGeneReviews™ [Internet]1993 Seattle: University of Washington, Seattle2014
Not in our library
163.
Stogbauer F Young P Kuhlenbaumer G De Jonghe P Timmerman V Hereditary recurrent focal neuropathies: clinical and molecular featuresNeurology2000 54546551
Not in our library10.1212/wnl.54.3.546
164.
Infante J Garcia A Combarros O Mateo JI Berciano J Sedano MJ Gutierrez-Rivas EJ Palau F Diagnostic strategy for familial and sporadic cases of neuropathy associated with 17p11.2 deletionMuscle Nerve2001 2411491155
Not in our library10.1002/mus.1126
165.
Andersson PB Yuen E Parko K So YT Electrodiagnostic features of hereditary neuropathy with liability to pressure palsiesNeurology2000 544044
Not in our library10.1212/wnl.54.1.40
166.
Li J Krajewski K Shy ME Lewis RA Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the nameNeurology2002 5817691773
Not in our library10.1212/wnl.58.12.1769
167.
Hong YH Kim M Kim HJ Sung JJ Kim SH Lee KW Clinical and electrophysiologic features of HNPP patients with 17p11.2 deletionActa Neurol Scand2003 108352358
Not in our library10.1034/j.1600-0404.2003.00132.x
168.
Gabreels-Festen A Wetering RV Human nerve pathology caused by different mutational mechanisms of the PMP22 geneAnn N Y Acad Sci1999 883336343
Not in our library
169.
Amato AA Barohn RJ Hereditary neuropathy with liability to pressure palsies: assocation with central nervous system demyelinationMuscle Nerve1996 19770773
Not in our library10.1002/(sici)1097-4598(199606)19:6<770::aid-mus13>3.0.co;2-p
170.
Sanahuja J Franco E Rojas-Garcia R Gallardo E Combarros O Begue R Granes P Illa I Central nervous system involvement in hereditary neuropathy with liability to pressure palsies: description of a large family with this associationArch Neurol1911–1914 200562
Not in our library10.1001/archneur.62.12.1911
171.
Tackenberg B Moller JC Rindock H Bien S Sommer N Oertel WH Rosenow F Schepelmann K Hamer HM Bandmann O CNS involvement in hereditary neuropathy with pressure palsies (HNPP)Neurology2006 6722502252
Not in our library10.1212/01.wnl.0000249185.78359.06
172.
Nicholson GA Valentijn LJ Cherryson AK Kennerson ML Bragg TL DeKroon RM Ross DA Pollard JD McLeod JG Bolhuis PA Baas F A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsiesNat Genet1994 6263266
Not in our library10.1038/ng0394-263
173.
Schenone A Nobbio L Mandich P Bellone E Abbruzzese M Aymar F Mancardi GL Windebank AJ Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsiesNeurology1997 48445449
Not in our library10.1212/wnl.48.2.445
174.
Schenone A Nobbio L Caponnetto C Abbruzzese M Mandich P Bellone E Ajmar F Gherardi G Windebank AJ Mancardi G Correlation between PMP-22 messenger RNA expression and phenotype in hereditary neuropathy with liability to pressure palsiesAnn Neurol1997 42866872
Not in our library10.1002/ana.410420607
175.
Jankelowitz SK Burke D Pathophysiology of HNPP explored using axonal excitabilityJ Neurol Neurosurg Psychiatry2013 84806812
Not in our library10.1136/jnnp-2012-304576
176.
Bai Y Zhang X Katona I Saporta MA Shy ME O’Malley HA Isom LL Suter U Li J Conduction block in PMP22 deficiencyJ Neurosci2010 30600608
Not in our library10.1523/jneurosci.4264-09.2010
177.
Hooper DR Lawson W Smith L Baker SK Sonographic features in hereditary neuropathy with liability to pressure palsiesMuscle Nerve2011 44862867
Not in our library10.1002/mus.22199
178.
Ginanneschi F Filippou G Giannini F Carluccio MA Adinolfi A Frediani B Dotti MT Rossi A Sonographic and electrodiagnostic features of hereditary neuropathy with liability to pressure palsiesJ Peripher Nerv Syst2012 17391398
Not in our library10.1111/j.1529-8027.2012.00437.x
179.
Stockton DW Meade RA Netscher DT Epstein MJ Shenaq SM Shaffer LG Lupski JR Hereditary neuropathy with liability to pressure palsies is not a major cause of idiopathic carpal tunnel syndromeArch Neurol2001 5816351637
Not in our library10.1001/archneur.58.10.1635
180.
Kuhlenbaumer G Hannibal MC Nelis E Schirmacher A Verpoorten N Meuleman J Watts GD De Vriendt E Young P Stogbauer F Halfter H Irobi J Goossens D Del-Favero J Betz BG Hor H Kurlemann G Bird TD Airaksinen E Mononen T Serradell AP Prats JM Van Broeckhoven C De Jonghe P Timmerman V Ringelstein EB Chance PF Mutations in SEPT9 cause hereditary neuralgic amyotrophyNat Genet2005 3710441046
Not in our library10.1038/ng1649
181.
Cruz-Martinez A Arpa J Palau F Peroneal neuropathy after weight lossJ Peripher Nerv Syst2000 5101105
Not in our library10.1046/j.1529-8027.2000.00007.x
182.
Kalfakis N Panas M Karadima G Floroskufi P Kokolakis N Vassilopoulos D Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatmentNeurology2002 5914701471
Not in our library10.1212/01.wnl.0000032505.45389.94
183.
Russo M Laura M Polke JM Davis MB Blake J Brandner S Hughes RA Houlden H Bennett DL Lunn MP Reilly MM Variable phenotypes are associated with PMP22 missense mutationsNeuromuscul Disord2011 21106114
Not in our library10.1016/j.nmd.2010.11.011
184.
Li J Parker B Martyn C Natarajan C Guo J The PMP22 gene and its related diseasesMol Neurobiol2013 47673698
Not in our library10.1007/s12035-012-8370-x
185.
De Vries SD Verhamme C Van Ruissen F Van Paassen BW Arts WF Kerkhoff H Van Engelen BG Lammens M De Visser M Baas F van der Kooi AJ The phenotype of the Gly94fsX222 PMP22 insertionJ Peripher Nerv Syst2011 16113118
Not in our library10.1111/j.1529-8027.2011.00333.x
186.
Saporta AS Sottile SL Miller LJ Feely SM Siskind CE Shy ME Charcot-Marie-Tooth disease subtypes and genetic testing strategiesAnn Neurol2011 692233
Not in our library10.1002/ana.22166
187.
Nelis E Holmberg B Adolfsson R Holmgren G Van Broeckhoven C PMP22 Thr(118)Met: recessive CMT1 mutation or polymorphism?Nat Genet1997 151314
Not in our library10.1038/ng0197-13
188.
Parman Y Plante-Bordeneuve V Guiochon-Mantel A Eraksoy M Said G Recessive inheritance of a new point mutation of the PMP22 gene in Dejerine-Sottas diseaseAnn Neurol1999 45518522
Not in our library10.1002/1531-8249(199904)45:4<518::aid-ana15>3.0.co;2-u
189.
Numakura C Lin C Oka N Akiguchi I Hayasaka K Hemizygous mutation of the peripheral myelin protein 22 gene associated with Charcot-Marie-Tooth disease type 1Ann Neurol2000 47101103
Not in our library

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.